Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

MLA

Alvarez-Larrán, Alberto, et al. “Real-World Analysis of Main Clinical Outcomes in Patients with Polycythemia Vera Treated with Ruxolitinib or Best Available Therapy after Developing Resistance/Intolerance to Hydroxyurea.” Cancer, vol. 128, no. 13, July 2022, pp. 2441–48. EBSCOhost, https://doi.org/10.1002/cncr.34195.

APA

Alvarez-Larrán, A., Garrote, M., Ferrer-Marín, F., Pérez-Encinas, M., Mata-Vazquez, M. I., Bellosillo, B., Arellano-Rodrigo, E., Gómez, M., García, R., García-Gutiérrez, V., Gasior, M., Cuevas, B., Angona, A., Gómez-Casares, M. T., Martínez, C. M., Magro, E., Ayala, R., Del Orbe-Barreto, R., Pérez-López, R., … Pereira, A. (2022). Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer, 128(13), 2441–2448. https://doi.org/10.1002/cncr.34195

Chicago

Alvarez-Larrán, Alberto, Marta Garrote, Francisca Ferrer-Marín, Manuel Pérez-Encinas, M Isabel Mata-Vazquez, Beatriz Bellosillo, Eduardo Arellano-Rodrigo, et al. 2022. “Real-World Analysis of Main Clinical Outcomes in Patients with Polycythemia Vera Treated with Ruxolitinib or Best Available Therapy after Developing Resistance/Intolerance to Hydroxyurea.” Cancer 128 (13): 2441–48. doi:10.1002/cncr.34195.